Clinical Trial Update: Buprenorphine Transdermal Patches (BTDS) in Subjects With Osteoarthritis Pain. Includes a 52-week Extension Phase. [Phase 3]

View source ↗

Summary

A Phase 3 study of buprenorphine transdermal patches for osteoarthritis pain, including a 52-week extension, sponsored by Purdue Pharma; the trial was terminate…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Osteoarthritis

Drugs mentioned

• Buprenorphine transdermal patch (buprenorphine)

Snippet

Sponsor: Purdue Pharma LP | Conditions: Osteoarthritis | Phase 3 | Status: TERMINATED | Results posted: 2010-09-20